Table 1.

Summary of clinicopathologic and molecular features in 240 patients with uveal melanoma

Variable	Summary Data (N=240)
Age at diagnosis (years)
Mean	62.4
Median	64 (14 to 93)
Sex
Female	121 (50.4%)
Male	119 (49.6%)
Largest basal diameter (mm)
Mean	14.6
Median (range)	15.0 (3 to 24)
No. of tumors with LBD < 12	60 (25.0%)
No. of tumors with LBD ≥ 12	180 (75.0%)
Thickness (mm)
Mean	6.9
Median (range)	6.4 (1.2 to 16.4)
Ciliary body involvement
Yes	104 (43.3%)
No	136 (56.7%)
Extraocular extension
Yes	17 (7.1%)
No	51 (21.3%)
Unable to be assessed	172 (72.0%)
Gene expression profile
Class 1	128 (53.3%)
Class 2	112 (46.7%)
PRAME status
PRAME (−)	157 (65.4%)
PRAME (+)	83 (34.6%)
Gene expression profile and PRAME status
Class 1 PRAME (−)	90 (37.5%)
Class 1 PRAME (+)	38 (15.8%)
Class 2 PRAME (−)	67 (27.9%)
Class 2 PRAME (+)	45 (18.8%)
TNM stage
I	26 (10.8%)
IIA	67 (27.9%)
IIB	50 (20.8%)
IIIA	59 (24.6%)
IIIB	38 (15.8%)
Metastasis
Yes	59 (24.6%)
No	181 (75.4%)
Last status
Alive without metastasis	175 (72.9%)
Alive with metastasis	23 (9.6%)
Melanoma specific mortality	36 (15.0%)
Non-melanoma specific mortality	6 (2.5%)
Treatment
Observation	1 (0.4%)
Plaque brachytherapy	165 (68.8%)
Enucleation	74 (30.8%)
Follow-up (months)
Mean	42
Median (Range)	29 (1 to 195)

Abbreviations: TNM, Tumor-Node-Metastasis; PRAME, preferentially expressed antigen in melanoma.